Vectura is a provider of innovative inhaled drug delivery services that enable partners to bring their medicines to patients. With differentiated proprietary technology and pharmaceutical development expertise, Vectura is one of the few companies globally with the device, formulation and development capabilities to deliver a broad range of complex inhaled therapies.
Vectura has thirteen key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz (a division of Novartis AG), Mundipharma, Kyorin, GSK, Bayer, Chiesi, Almirall, and Tianjin KingYork.
For further information, please visit Vectura's website at www.vectura.com
Location: United Kingdom, England, Chippenham
Member count: 201-500
Founded date: 1997
Investors 1
| Date | Name | Website |
| - | Life Scien... | lspvc.com |
Mentions in press and media 6
| Date | Title | Description | Category | Author | Source |
| 09.08.2021 | Is being S... | Happy Monday, Term Sheet reade... | - | - | fortune.co... |
| 09.08.2021 | Is being S... | This is the web version of Ter... | - | - | fortune.co... |
| 12.07.2021 | In Didi’s ... | This is the web version of Ter... | - | - | fortune.co... |
| 10.06.2021 | VECTURA GR... | Published:10/06/2021 Vectura ... | - | - | marketscre... |
| 21.04.2021 | VECTURA GR... | Published:21/04/2021 Vectura ... | - | - | marketscre... |
| 22.09.2020 | VECTURA GR... | Published:22/09/2020 Vectura ... | - | - | marketscre... |